Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“Menin inhibitor monotherapy trials in relapse refractory leukemia:
- Meaningful activity in RR leukemia, especially in molecularly selected patients with KMT2Ar or NPM1-m: 20-30%.
- Differentiation syndrome is a class effect, and QTc prolongation has been reported around 10-15%.
- Durability of responses: median DoR ~4–7 months.
which has led to exploration of combination strategies.”
More posts featuring Talha Badar.